Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection
about
Long-term outcomes of heart transplant recipients with hepatitis C positivity: the data from the U.S. transplant registry.Effect of kidney donor hepatitis C virus serostatus on renal transplant recipient and allograft outcomesDo we really need more evidence to use hepatitis C positive donor kidney more liberally?Use of direct-acting agents for hepatitis C virus-positive kidney transplant candidates and kidney transplant recipients.Direct-acting antiviral agent efficacy and safety in renal transplant recipients with chronic hepatitis C virus infection: A PRISMA-compliant study.Kidney transplant recipients with hepatitis C virus experienced 100% sustained virologic response at 12 weeks when treated with sofosbuvir-ledipasvir.Development of proteinuria and focal segmental glomerulosclerosis during direct-acting antiviral therapy for hepatitis C virus infection.Efficacy and safety of sofosbuvir and daclatasvir in treatment of kidney transplantation recipients with hepatitis C virus infection.When and how can nephrologists treat hepatitis C virus infection in dialysis patients?Direct-Acting Antivirals in Kidney Transplant Patients: Successful Hepatitis C Treatment and Short-Term Reduction in Urinary Protein/Creatinine Ratios.Recommendations for the treatment of hepatitis C virus infection in chronic kidney disease: a position statement by the Spanish association of the liver and the kidney.Letter: should direct-acting antiviral drugs be used concomitantly with chemotherapeutic drugs in hepatitis C virus-infected patients with cancer?Successful Recovery of Acute Renal Transplant Failure in Recurrent Hepatitis C Virus-Associated Membranoproliferative Glomerulonephritis.Transplantation of Kidneys from HCV-Positive Donors: How to Best Use a Scarce Resource.Transplant glomerulopathy.Sofosbuvir-based regimens for the treatment of chronic hepatitis C in severe renal dysfunction.Role of Direct Antiviral Agents in Treatment of Chronic Hepatitis C Infection in Renal Transplant Recipients.
P2860
Q31136569-499E24B0-F20B-46F4-8044-199471455634Q38602837-1389142F-8E17-44C2-9495-2DEBBA4470BCQ38611051-7C0C55F6-EF7B-4B77-95F9-CFFA071F5272Q38975165-1CA7376D-AC94-4080-860E-ABA01DB11B26Q40107697-DE514325-70FA-4596-824F-33C239808346Q40145496-BA4A3806-ECA4-43CA-B6E7-7D313F3B9984Q40328412-064A1C67-F134-483F-B3C0-B9A79B435913Q41608541-50E4C4D6-5201-499C-B940-8D2226C31EA0Q41934901-2986CB9D-A285-4A89-9C1A-1E7CE1222511Q42640856-42EA72C7-5D4F-4275-883F-266E010A2DFCQ45325791-95E6754A-277A-4ED6-83B0-4738FB54E5BBQ45330701-3EEB8D5A-8979-4EC9-9B62-A404063ABBEBQ45332478-AD663360-B859-4F71-BADC-573925133866Q47777226-A7CDFA50-FB32-422B-AD1A-8D43B2DA5764Q50063069-76E0C41F-7D07-4078-AC55-5A398EEF20FCQ51754955-D0B27B96-2CDF-4F1F-BCD6-070FB0A1F8BEQ55191989-1CA25A31-1AEF-49E0-AEF6-4BB39C624A81
P2860
Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Efficacy and Safety of Direct ...... ic Hepatitis C Virus Infection
@ast
Efficacy and Safety of Direct ...... ic Hepatitis C Virus Infection
@en
type
label
Efficacy and Safety of Direct ...... ic Hepatitis C Virus Infection
@ast
Efficacy and Safety of Direct ...... ic Hepatitis C Virus Infection
@en
prefLabel
Efficacy and Safety of Direct ...... ic Hepatitis C Virus Infection
@ast
Efficacy and Safety of Direct ...... ic Hepatitis C Virus Infection
@en
P2093
P2860
P1433
P1476
Efficacy and Safety of Direct ...... ic Hepatitis C Virus Infection
@en
P2093
Anil Chandraker
Anna E Rutherford
Beth M Amundsen
Donald Chute
Eliot C Heher
Jasmine M Hanifi
Leonardo V Riella
Martha Pavlakis
Meghan E Sise
Michael P Curry
P2860
P304
P356
10.1371/JOURNAL.PONE.0158431
P407
P577
2016-07-14T00:00:00Z